Benzinga··Brainstorm Cell Therapeutics Inc.BrainStorm Cell Narrows Q1 Loss, Advances ALS Phase 3b Trial Amid Tight Cash
BrainStorm Cell Therapeutics narrowed Q1 net loss to $2.1M while raising $2.2M for Phase 3b ALS trial preparation, though cash reserves stand at just $0.2M.
BCLIneurodegenerative diseasesBLA submission